Best Oncology Companies in San Francisco, United States

Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.

Funding rounds

• May 2026Post IPO$40M
• Dec 2024Post IPO$37.6M
• Dec 2024Post IPO$10M
• Jun 2024Grant (prize money)$8M

Founders & team

Jim CollinsCo-FounderWilson WongCo-FounderTim LuCo-Founder & CEO

Investors

Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch

Developer of small-molecule therapeutics for cancer treatment. It provides a lysine-targeted covalency platform to develop therapies against known drug targets for oncology.

Funding rounds

• Apr 2026Series C$108M
• Nov 2023Series B$175M
• May 2022Series A$75M

Founders & team

Matt JacobsonCo-FounderJack TauntonCo-FounderPeter ThompsonCo-Founder & CEO

Investors

Orbimed, Third Rock Ventures, EcoR1, Novo Holdings, Cormorant Capital, RA Capital Management

Tech stack

All In One SeoAmazon Web ServicesApple Icloud MailBugherdCdnjsCloudflare

Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.

Funding rounds

• Apr 2026Series A$5M
• Jun 2025Series A$25.4M
• Jul 2023Series A$48.5M
• Jun 2021Series A$60M

Founders & team

Manish AgarwalCo-FounderScott BratmanCo-Founder

Investors

F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp

Developing targeted, immune-mediated oral cancer therapies for broad patient benefit. This clinical-stage biotechnology company focuses on creating small molecule therapeutics to treat cancer. Their approach involves mechanisms that directly target and kill tumor cells while simultaneously activating the body's own tumor-specific immunity. The company is developing first-in-class oral drug therapeutics with the potential to offer significant advantages to a wide range of cancer patients. They explore both new and validated pathways to discover and develop novel therapeutics. Their pipeline represents innovative approaches to cancer treatment, aiming to improve patient outcomes through targeted and immune-mediated strategies. The company's focus is on oncology drug discovery and development, with the goal of advancing novel therapeutics that will bring meaningful benefit to patients.

Funding rounds

• Mar 2026Post IPO$6M
• Mar 2026Post IPO$2M
• Feb 2020Series B$83.2M
• 2015Series A—

Founders & team

Stephen BChief Executive Officer

Investors

F-Prime Capital, Lilly Asia Ventures, Foresite Capital, Eight Roads Ventures, Versant Ventures, Quan Capital

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Developer of resistance mechanism inhibitors to treat cancer. It targets multiple hallmarks of cancer progression and have demonstrated efficacy as monotherapy and in strategic combinations. The lead drug program OS2966 therapeutic antibody blocking a cell surface receptor for the treatment of glioblastoma, ovarian, pancreatic cancer, and malignant meningioma.

Developer of therapeutics for immunology and cancer. The company is developing transformative therapies by using a technology that maps human tissue and manipulates Tregs and other immune cells in a tissue-specific and disease-specific fashion.

Funding rounds

• Jan 2026Series B$50M
• Nov 2024Series B$84M
• Mar 2022Series A$26M
• Jun 2021Series A$59M

Founders & team

Johnston ErwinCEO

Investors

Polaris Partners, SV Health Investors, Lilly, Johnson & Johnson Innovation, Pfizer, Alexandria

Developer of CAR- T therapy for cancer treatment. The lead CAR program LYL797is developed for the treatment of ROR1+ non-small cell lung cancer and triple-negative breast cancer. Another candidate LYL845 is an autologous TIL therapy for the treatment of multiple solid tumors.

Funding rounds

• Jul 2025Post IPO$100M
• Mar 2020Series C$493M
• 2018Seed—

Founders & team

Stan RiddellCo-FounderCrystal MackallCo-FounderRick KlausnerCo-Founder

Investors

GSK, Sahsen Ventures, 8VC, Foresite Capital, Arch Venture Partners, Mubadala

Tech stack

Amazon Web ServicesBootstrapCloudflareCloudflare Bot ManagementFont AwesomeGoogle Analytics

Developer of therapies for immunological diseases and cancer. The company focuses on the development of therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. The company's lead product ELA026, is a monoclonal antibody to treat secondary hemophagocytic lymphohistiocytosis (sHLH).

Funding rounds

• Oct 2025Series C$183M
• Dec 2023Series B—
• Feb 2022Series B$84M

Founders & team

Adam RosenthalCo-Founder & CEO

Investors

Westlake Village Biopartners, Orbimed, Redmile Group, Cormorant Asset Management, Cowen, New Leaf Venture Partners

Developer of small-molecule drugs for the treatment of cancers. The company is focused on the discovery and development of small-molecule drugs that target treatment-resistant cancers which involve glucocorticoid receptor activation. The company's product line include ORC-101 is used for the treatment of solid tumours.

Provider of molecular diagnostic testing services for identifying cancer vulnerabilities. This service maps tumor biology across DNA, RNA, and protein layers to reveal actionable therapeutic targets. The process utilizes whole genome sequencing, RNA sequencing, and proteomic analysis to assess tumor heterogeneity and resistance mechanisms. Results are integrated into a digital format for review by medical professionals to inform treatment decisions. The analysis compares individual tumor samples against biological datasets to evaluate pathway activation and potential treatment options.

Funding rounds

• Mar 2026Series A$10M

Founders & team

Sarah HesseCo-Founder & Head of Translational ScienceEdward LarkinCo-Founder & CEOClaire OldfieldCo-Founder & COO

Investors

8VC, Basis Set Ventures, Define Ventures

Developer of therapeutics for treating diseases caused by dysfunctional genome chromatin packaging. The company's proprietary platform addresses major limitations and challenges seen in the healthcare space by recreating the biological context of cancer-driving chromatin states in a controlled, cell-free environment. It focuses on disrupting or restoring the unique protein-protein and protein-DNA networks that package cell genomes.

Funding rounds

• Apr 2026Seed$4.5M
• Seed$2.5M

Founders & team

Geeta NarlikarCo-FounderLaura HsiehCo-Founder & CEO

Investors

SOSV, Primer Sazze Partners, freeflow, StoryHouse Ventures, The Sontag Foundation, BrightEdge

Tech stack

CdnjsCloudflareCore-JsGoogle Font ApiGoogle Hosted LibrariesGoogle Maps

Provider of personalized nutritional programs against cancer. The company offers the Faeth program, a precision cancer treatment that uses metabolism to starve cancer cells, depriving and providing resistance to standard treatments. The program includes meals, therapeutics, and on-demand support from Faeth nutritionists.

Funding rounds

• Aug 2025Series A$25M
• Jun 2022Series A$47M
• Jan 2022Seed$20M

Founders & team

Anand ParikhFounder & CEO

Investors

Khosla Ventures, Future Ventures, Digitalis Ventures, KdT Ventures, AgFunder, Cantos Ventures

Tech stack

CloudflareDocusignGoogle Font ApiGoogle Hosted LibrariesGoogle WorkspaceHsts